Bill brings extensive neuroscience drug development expertise to leading Calico’s Clinical Science group. He collaborates closely with AbbVie on bringing our research into the clinic and ultimately to patients. He also collaborates internally with Business Development and early stage research teams to provide a translational perspective on the evaluation of pipeline opportunities and basic research discoveries.
Bill came to Calico from Genentech where he was Senior Medical Director, Early Clinical Development, focused on a number of programs in Genentech’s neuroscience portfolio, including compounds for Alzheimer’s Disease, ALS, Parkinson’s Disease, and Pain. In this role, Bill led cross-functional teams responsible for designing and executing clinical development programs from pre-IND through Phase IIb studies. Prior to Genentech, Bill held roles of increasing responsibility in Merck’s Clinical Pharmacology and Experimental Medicine groups, focused on biomarker and clinical development of neuroscience compounds.
- Residency and Postdoc in Psychiatry, University of California at San Francisco
- M.D., University of Michigan Medical School
- Ph.D. in Neuroscience, University of Michigan Medical School
- B.A. in Biology and Chemistry, Kalamazoo College